Erlotinib
Drug Details
- Description
- Erlotinib is an oral tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR), used primarily in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. It works by inhibiting tumor cell proliferation and promoting apoptosis.
- Alternative Names
- Erlotinib is also known by the brand name Tarceva.
- Key Genes
- Key genes involved with erlotinib include EGFR (Epidermal Growth Factor Receptor) and KRAS.
- Drug Use
- Erlotinib is used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. It targets and inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in cancer cell growth.
- Genetic Factors Influencing Response
-
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Purchase Membership to Access Your Individual Drug Response Report